Form 20-F BiondVax Pharmaceuticals For: Dec 31 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
BiondVax Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
USA - English
Share this article
JERUSALEM, May 13, 2021 /PRNewswire/
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses, today published its fourth quarter and full year financial results for the year ended December 31, 2020 and provided a business update.
Fourth Quarter 2020 Financial Summary
Results are in New Israel Shekels (NIS) and convenience translation to US$ is provided using the exchange rate of 3.215 (NIS/US$), the rate as of the close of business on December 31, 2020.
(Pixabay)
Welcome to this week s Chutes & Ladders, our roundup of hirings, firings and retirings throughout the industry. Please send the good word or the bad from your shop to Fraiser Kansteiner, and we will feature it here at the end of each week.
Another GSK vaccine exec jumps ship for biotech CEO role
GlaxoSmithKline
Amir Reichman is stepping down.
Reichman is leaving his post as head of global vaccines engineering core technology at GSK to eventually head up operations at BiondVax Pharmaceuticals. Reichman will split duties with BiondVax’s founder and CEO Ron Babecoff until March 2 as he wraps his time at GSK. Reichman joined GSK in 2015 as part of a multibillion-dollar deal that saw GSK trade off its oncology assets for Novartis’ vaccines unit. Reichman held various positions at Novartis in its vaccine supply chain unit before becoming director of GSK’s global vaccines supply chain and then head of global vaccines engineering
(2)
INDIANAPOLIS (dpa-AFX) - Today s Daily Dose brings you news about the effectiveness of Lilly s Bamlanivimab in reducing the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities, executive changes at BiondVax Pharma, regulatory update on Genetic Technologies COVID-19 PRS Test, Adamis SYMJEPI products being made available in the Walgreens Prescription Savings Club, Fluidigm s Advanta Dx SARS-CoV-2 RT-PCR Assay receiving the CE-IVD mark.
Read on.
1. Adamis to Offer SYMJEPI in Walgreens Prescription Savings Club
Adamis Pharmaceuticals Corporation (ADMP) surged more than 90% in after-hours Thursday, on news of its SYMJEPI products now being available to members of the Walgreens Prescription Savings Club program.